 |
 |
Current State of Malignant Hyperthermia And the Use of Dantrium IV as Treatment
Malignant hyperthermia (MH) is an autosomally inherited disorder characterized by an increase in heart rate, respiratory rate, body temperature, and muscle rigidity when the patient is exposed to potent volatile anesthetic gases and succinylcholine. The prevalence and incidence of MH are difficult to determine because patients display no characteristic signs until anesthetized with one of the triggering agents, and even then do not always develop the disorder. This article discusses the clinical presentation of MH, treatment using Dantrium® IV, and provides information on educational resources such as the Malignant Hyperthermia Association of the United States.
To request a free hard copy of this Bench to Bedside article, please email your full name, mailing address, and institution to anesthesiologynews@mcmahonmed.com
MARCH 2010 |
|
|
|
|
|
 |
Managing Cancer-Related Breakthrough Pain With FENTORA
Breakthrough pain (BTP) in patients
with cancer is a common, distressing
and costly problem. It interferes
with functional capacities and virtually all
quality-of-life measures, and adds appreciably
to physical and psychological morbidity.
OCTOBER 2007 |
|
See more in the Bench to Bedside Archives |
2
